The Breakup of Warner Bros Discovery – The Special Situations Report Episode #23

Episode Summary

Executive Summary: Episode 23 of Special Situations Report surveyed a wide range of event-driven catalysts: Keros Therapeutics chose a partial capital return instead of a full liquidation, Forward Air drew PE takeover interest amid post-acquisition distress, several food and telecom deals emerged, BioNTech agreed to buy CureVac, Warner Bros. Discovery unveiled a major spin-off, IMAX expanded buybacks, and multiple insider/activist moves signaled changing governance and M&A dynamics across biotech, media, trucking, pharma, and consumer names.

Main Topics: Keros Therapeutics and the 'zombie biotech' playbook (Priority: 5/5): The hosts revisited their zombie biotech framework and noted Keros decided not to sell itself, instead planning to return $370 million of excess capital to shareholders. They framed it as a partial win because the company still retains substantial cash and continues operating. Forward Air takeover interest and trucking-sector consolidation (Priority: 5/5): Private equity interest from firms like Blackstone and Apollo in Forward Air was discussed in the context of the company's failed Omni Logistics acquisition, leverage, operational losses, and activist pressure from Ancora. The hosts contrasted it with Heartland Express and broader trucking-industry consolidation potential. New and rumored M&A across consumer, telecom, and biotech (Priority: 5/5): The episode covered a non-binding $32/share proposal for Calavo Growers, Apollo and a Qatari fund's bid for Papa John's, TELUS's offer for the remainder of TELUS International, and BioNTech's $1.25 billion merger with CureVac. The hosts emphasized deal structure, premiums, and spread behavior. Warner Bros. Discovery breakup and spin-off structure (Priority: 4/5): The hosts examined WBD's plan to separate streaming/studios from global networks, noting the likely division of assets, leadership assignments, debt considerations, and the possibility that the spin-off could resemble the Lionsgate/Starz split in unexpected ways. IMAX buyback and operating momentum (Priority: 3/5): IMAX announced a $100 million repurchase authorization increase within a larger buyback program. The hosts linked the company's strong stock performance and margins to a strong slate of films and improving financials. Insider buying and activist positioning in biotech, pharma, and consumer names (Priority: 4/5): The show highlighted insider purchases at Quanterix and Bausch Health, plus activist developments at Lamb Weston, Provident Bancorp, and Novo Nordisk. These were framed as signals of management confidence, governance tension, or strategic uncertainty.

Key Arguments: Keros's decision to return only part of its cash balance is a compromise for shareholders, not the full wind-down many expected. Forward Air's depressed valuation and operational distress could make it an attractive turnaround or take-private candidate despite trucking's low-margin profile. A deal for Forward Air could benefit other trucking companies by encouraging sector consolidation and revaluation. Several announced or rumored deals still trade below or near proposed prices, showing that deal risk and negotiation remain central in special situations. TELUS International trading above the proposed buyout price suggests minority holders may be trying to force a higher bid. BioNTech's CureVac deal is notable not just for valuation but for the collar mechanism that adjusts the exchange ratio with BioNTech's share price. WBD's split appears to separate the better growth assets from legacy cable assets, but the market may not reward that simple narrative, as seen in Lionsgate/Starz. IMAX's buyback signals confidence, but the company's share-price strength may already reflect recent box-office tailwinds. Insider buying by Quanterix management suggests internal conviction in the Akoya acquisition despite external shareholder opposition. John Paulson's purchase of Bausch Health is intriguing because the company remains highly leveraged and structurally challenged, yet insiders may see value the market misses. Activists like Jana Partners and PowerWorks are trying to influence board composition and CEO selection in situations where strategic change is underway. C-suite transitions at Paramount and Roblox show how capital markets and growth profiles differ sharply across mature media and high-growth digital platforms.

Data Points: Keros cash balance: ~$720 million - Balance sheet cash cited while discussing the company's partial capital return Keros capital return: $370 million - Excess capital management plans to return to stockholders Forward Air stock decline: nearly half of value lost in 2024 - Following the Omni Logistics acquisition and subsequent losses Forward Air acquisition price for Omni Logistics: $3.2 billion - Deal that contributed to leverage and operating pressure Forward Air share price before Omni deal: $120 - Referenced as the pre-announcement stock price Forward Air current share price: around $20 - Trading level during the episode Forward Air market cap: $615 million - Used for comparison with Heartland Express Forward Air enterprise value: $2.72 billion - Highlights leverage burden Heartland Express market cap: $683 million - Comparison trucking peer Heartland Express enterprise value: $865 million - Comparison trucking peer Heartland forward EV/EBITDA: under 6x - Valuation cited during comparison Forward Air forward EV/EBITDA: around 9x - Valuation cited during comparison Ancora stake in Forward Air: 4% - Activist stake that pushed the company to consider a sale Calavo Growers proposal price: $32 per share - Non-binding bid to acquire all outstanding shares Calavo current trading price: $27.66 - Used to assess premium Calavo buyback announced in March: $25 million - Earlier repurchase authorization mentioned by hosts Calavo buyback size as % of market cap: about 6% - Context for prior buyback Papa John's bid: low $60s per share - Reported Apollo/Qatari offer range Papa John's current trading price: $50.42 - Compared with rumored bid TELUS International offer price: $3.40 per share - TELUS Corp's proposal for minority shares TELUS Corporation ownership of TELUS International: 60.1% - Majority stake already held TELUS International trading price: $3.61 - Trading above the offer price TELUS International premium/discount: about 21 cents above offer - Negative spread to proposed buyout price BioNTech-CureVac deal value: $1.25 billion - Merger agreement announced this week CureVac share exchange value: about $5.46 in BioNTech ADRs - Equivalent per-share consideration CureVac premium: about 34.15% - Premium to last close BioNTech collar upper trigger: $126.55 - 10-day VWAP threshold for exchange ratio adjustment BioNTech collar lower trigger: $84.37 - 10-day VWAP threshold for exchange ratio adjustment WBD spin-off expected timing: mid-2026 - Expected completion window IMAX buyback announcement: $100 million - New repurchase authorization increase IMAX total repurchase authorization: $500 million - Cumulative authorization after increase IMAX remaining authorization: approximately $250 million - Amount still available for repurchases IMAX stock performance: up 84% in the last year - Context for strong recent performance IMAX gross margin: 54.62% - Financial performance cited IMAX net margin: almost 7% - Financial performance cited Quanterix cash balance: $267 million - Compared against the company's market cap in the Akoya deal discussion Quanterix market cap: around $235 million - Used to argue for returning capital instead of acquiring Akoya Bausch Health debt: $21.5 billion - Explains leverage concerns despite insider buying Bausch Health market cap: $2.21 billion - Highlights capital structure imbalance Bausch Health stock move after Paulson purchase: up over 18% - Market reaction after director John Paulson's buying Lamb Weston stake by Jana Partners: 11% - Activist ownership level after increase Provident Bancorp activism exit: shares sold after merger announcement - Stilwell Value exited after NB Bancorp deal

Pivotal Quotes: "Zombie biotechs are biotech companies that are flush with cash on the balance sheet and trade below net cash, often because they aren't making any scientific progress." — Asif Surya: Definition introduced while revisiting the Keros Therapeutics situation "Quite frankly, I have to say, I'm very surprised that a PE firm like Apollo might be interested in buying a trucking company, which usually is known for low margins and being an asset-heavy company." — Samanas Surya: Reaction to reported PE interest in Forward Air "If the 10-day volume weighted average price of BioNTech exceeds $126.55, the exchange ratio will be 0.04318." — Asif Surya: Explaining the collar mechanism in the BioNTech-CureVac merger

Implications: The episode signals that cash-rich biotechs, levered roll-ups, and stressed asset-heavy companies remain fertile ground for activism and take-private interest. Listeners should watch capital return plans, merger collars, and insider/board buying as clues to where value may be realized next.